RNA virus error catastrophe: Direct molecular test by using ribavirin

被引:665
作者
Crotty, S
Cameron, CE
Andino, R
机构
[1] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA
[2] Penn State Univ, Althouse Lab, Dept Biochem & Mol Biol, University Pk, PA 16802 USA
关键词
D O I
10.1073/pnas.111085598
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
RNA viruses evolve rapidly. One source of this ability to rapidly change is the apparently high mutation frequency in RNA virus populations. A high mutation frequency is a central tenet of the quasispecies theory. A corollary of the quasispecies theory postulates that, given their high mutation frequency, animal RNA viruses may be susceptible to error catastrophe, where they undergo a sharp drop in viability after a modest increase in mutation frequency. We recently showed that the important broad-spectrum antiviral drug ribavirin (currently used to treat hepatitis C virus infections, among others) is an RNA virus mutagen, and we proposed that ribavirin's antiviral effect is by forcing RNA viruses into error catastrophe. However, a direct demonstration of error catastrophe has not been made for ribavirin or any RNA virus mutagen. Here we describe a direct demonstration of error catastrophe by using ribavirin as the mutagen and poliovirus as a model RNA virus. We demonstrate that ribavirin's antiviral activity is exerted directly through lethal mutagenesis of the viral genetic material. A 99.3% loss in viral genome infectivity is observed after a single round of virus infection in ribavirin concentrations sufficient to cause a 9.7-fold increase in mutagenesis, Compiling data on both the mutation levels and the specific infectivities of poliovirus genomes produced in the presence of ribavirin, we have constructed a graph of error catastrophe showing that normal polio-virus indeed exists at the edge of viability. These data suggest that RNA virus mutagens may represent a promising new class of antiviral drugs.
引用
收藏
页码:6895 / 6900
页数:6
相关论文
共 51 条
[1]
*AM SOC HOSP PHARM, 2000, AFHS DRUG INF
[2]
[Anonymous], MOL BASIS VIRUS EVOL
[3]
STUDIES ON THE INFECTIVITY OF FOOT-AND-MOUTH-DISEASE VIRUS-RNA USING MICROINJECTION [J].
BELSHAM, GJ ;
BOSTOCK, CJ .
JOURNAL OF GENERAL VIROLOGY, 1988, 69 :265-274
[4]
MUTATIONS CONFERRING RESISTANCE TO NEUTRALIZATION WITH MONOCLONAL-ANTIBODIES IN TYPE-1 POLIOVIRUS CAN BE LOCATED OUTSIDE OR INSIDE THE ANTIBODY-BINDING SITE [J].
BLONDEL, B ;
CRAINIC, R ;
FICHOT, O ;
DUFRAISSE, G ;
CANDREA, A ;
DIAMOND, D ;
GIRARD, M ;
HORAUD, F .
JOURNAL OF VIROLOGY, 1986, 57 (01) :81-90
[5]
ISOLATION AND CHARACTERIZATION OF CONDITIONAL-LETHAL MUTANTS OF SINDBIS VIRUS [J].
BURGE, BW ;
PFEFFERKORN, ER .
VIROLOGY, 1966, 30 (02) :204-+
[6]
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen [J].
Crotty, S ;
Maag, D ;
Arnold, JJ ;
Zhong, WD ;
Lau, JYN ;
Hong, Z ;
Andino, R ;
Cameron, CE .
NATURE MEDICINE, 2000, 6 (12) :1375-1379
[7]
Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens:: Stimulation of humoral, mucosal, and cellular immunity [J].
Crotty, S ;
Lohman, BL ;
Lü, FXS ;
Tang, SB ;
Miller, CJ ;
Andino, R .
JOURNAL OF VIROLOGY, 1999, 73 (11) :9485-9495
[8]
A SET OF LACZ MUTATIONS IN ESCHERICHIA-COLI THAT ALLOW RAPID DETECTION OF EACH OF THE 6 BASE SUBSTITUTIONS [J].
CUPPLES, CG ;
MILLER, JH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (14) :5345-5349
[9]
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499
[10]
VERY HIGH-FREQUENCY OF REVERSION TO GUANIDINE RESISTANCE IN CLONAL POOLS OF GUANIDINE-DEPENDENT TYPE-1 POLIOVIRUS [J].
DELATORRE, JC ;
WIMMER, E ;
HOLLAND, JJ .
JOURNAL OF VIROLOGY, 1990, 64 (02) :664-671